



HAL
open science

Smartwatch Electrocardiogram and Artificial Intelligence for Assessing Cardiac-Rhythm Safety of Drug Therapy in the COVID-19 Pandemic. The QT-logs study

Baptiste Maille, Marie Wilkin, Matthieu Million, Noémie Resseguier, Frédéric Franceschi, Linda Koutbi-Franceschi, Jérôme Hourdain, Elisa Martinez, Maxime Zabern, Christophe Gardella, et al.

► To cite this version:

Baptiste Maille, Marie Wilkin, Matthieu Million, Noémie Resseguier, Frédéric Franceschi, et al.. Smartwatch Electrocardiogram and Artificial Intelligence for Assessing Cardiac-Rhythm Safety of Drug Therapy in the COVID-19 Pandemic. The QT-logs study. *International Journal of Cardiology*, 2021, 10.1016/j.ijcard.2021.01.002 . hal-03150049

HAL Id: hal-03150049

<https://hal.science/hal-03150049>

Submitted on 24 Apr 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **Smartwatch Electrocardiogram and Artificial Intelligence for Assessing Cardiac-**
2 **Rhythm Safety of Drug Therapy in the COVID-19 Pandemic**

3 **The QT-Logs Study**

4

5 Maille et al: QT-Logs study

6

7 **Baptiste Maille, MD, Marie Wilkin, MD, Matthieu Millon, MD, PhD, Noémie Ressayguier, MD, PhD,**
8 **Frédéric Franceschi, MD, PhD, Linda Koutbi-Franceschi, MD, Jérôme Hourdain, MD, Elisa**
9 **Martinez, MD, Maxime Zabern, MD, Christophe Gardella, PhD, Herve Dupont-Tissot, MD PhD,**
10 **Jagmeet P. Singh MD, DPhil, Jean-Claude Deharo, MD, Laurent Fiorina, MD**

11

12 **Affiliations**

13 Assistance Publique – Hôpitaux de Marseille, Centre Hospitalier Universitaire La Timone, Service de
14 Cardiologie, Marseille, France (B.M., M.W., F.F., L.K-F., J.H., E.M., M.Z., J-C.D.); Aix Marseille
15 University, C2VN, Marseille, France (B.M., M.W., F.F., L.K-F., J.H., E.M., M.Z., J-C.D.); IHU-
16 Méditerranée Infection, Marseille, France (M.M., H.D-T.); Department of Epidemiology and Health
17 Economics, APHM, Marseille, France (N.R.); Cardiologs Technologies, Paris, France (C.G.)
18 Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA (J.P.S.) ; Institut
19 Cardiovasculaire Paris-Sud, Hôpital Privé Jacques Cartier, Ramsay, Massy, France (L.F.)

20

21 Abbreviated title: Smartwatch ECG and AI for Assessing Cardiac-Rhythm Safety

22

23 **Correspondence:** Professor Jean-Claude Deharo, Hôpital La Timone Adultes, 264 Rue Saint Pierre,
24 13385 Marseille Cédex 05, France. Tel: +33491386590; Fax: +33491386470.

25 (jean-claude.deharo@ap-hm.fr)

1

2 Total word count: 5625

3 Main text word count: 3557

4 Abstract: 250 words

5

6 **Disclosures**

7 Jag Singh is consultant for Medtronic, Boston Scientific, Abbott Laboratories, Microport, EBR,
8 Cardiologs, Nopras Inc, Impulse Dynamics, Biotronik

9 Laurent Fiorina is consultant for Cardiologs Technologies[®], Paris, France.

10 Christophe Gardella is employed by Cardiologs Technologies[®], Paris, France as a data scientist.

11

12 The remaining authors have nothing to disclose.

1 **ABSTRACT**

2 **BACKGROUND:** QTc interval monitoring, for the prevention of drug-induced arrhythmias is
3 necessary, especially in the context of coronavirus disease 2019 (COVID-19). For the provision of
4 widespread use, surrogates for 12-lead ECG QTc assessment may be useful. This prospective
5 observational study compared QTc duration assessed by artificial intelligence (AI-QTc) (Cardiologs®,
6 Paris, France) on smartwatch single-lead electrocardiograms (SW-ECGs) with those measured on 12-
7 lead ECGs, in patients with early stage COVID-19 treated with a hydroxychloroquine–azithromycin
8 regimen.

9 **METHODS:** Consecutive patients with COVID-19 who needed hydroxychloroquine–azithromycin
10 therapy, received a smartwatch (Withings Move ECG®, Withings, France). At baseline, day-6 and
11 day-10, a 12-lead ECG was recorded, and a SW-ECG was transmitted thereafter. Throughout the
12 drug regimen, a SW-ECG was transmitted every morning at rest. Agreement between manual QTc
13 measurement on a 12-lead ECG and AI-QTc on the corresponding SW-ECG was assessed by the
14 Bland-Altman method.

15 **RESULTS:** 85 patients (30 men, mean age 38.3 ± 12.2 years) were included in the study. Fair
16 agreement between manual and AI-QTc values was observed, particularly at day-10, where the delay
17 between the 12-lead ECG and the SW-ECG was the shortest (-2.6 ± 64.7 min): 407 ± 26 ms on the 12-
18 lead ECG vs 407 ± 22 ms on SW-ECG, bias -1 ms, limits of agreement -46 ms to $+45$ ms; the
19 difference between the two measures was <50 ms in 98.2% of patients.

20 **CONCLUSION:** In real-world epidemic conditions, AI-QTc duration measured by SW-ECG is in fair
21 agreement with manual measurements on 12-lead ECGs. Following further validation, AI-assisted
22 SW-ECGs may be suitable for QTc interval monitoring.

23 **REGISTRATION:** ClinicalTrial.gov NCT04371744.

24 **Key Words:** COVID-19, hydroxychloroquine-azythromycine, QTc interval, smartwatch, artificial
25 intelligence

1 INTRODUCTION

2 The current pandemic due to a new coronavirus – severe acute respiratory syndrome coronavirus 2
3 (SARS-CoV-2) – has so far affected more than 11 million people and caused in excess of half a million
4 deaths. This healthcare emergency made it necessary to explore pharmacologic interventions to
5 treat or prevent the disease. The use of antiviral drugs is one such intervention, but their efficacy
6 remains debated and strategies for their use are evolutive.[1] In the absence of definitive proof of
7 effectiveness, the safety profile of any treatment is a crucial question. Cardiac toxicity is one of the
8 main concerns because many of the proposed treatments, including lopinavir/ritonavir,
9 chloroquine/hydroxychloroquine (HCQ), azithromycin (AZM), moxyfloxacin and remdesivir, have the
10 potential to cause proarrhythmia, particularly in the setting of severe forms of SARS-CoV2.[2, 3]
11 Monitoring the QT interval and cardiac rhythm are essential for safety considerations regarding the
12 use of these drugs. [3]

13 Some single-lead ECG devices coupled with artificial intelligence (AI) received US Food and Drug
14 Administration clearance for atrial-fibrillation screening,[4] but little is known about the feasibility
15 and diagnostic accuracy of their use for QTc assessment.[5] In light of the shortage of resources and
16 widespread use, and in the context of a highly contagious disease, surrogates for 12-lead
17 electrocardiogram (ECG) assessment may be useful, and direct-to-consumer single-lead ECG
18 technology is promising. If previous study had already shown a good agreement between QTc
19 measured on a Smartwatch ECG (SW-ECG) and a 12 leads ECG,[6] little is known about the use of AI
20 for QTc measurement. The Cardiologs Platform (Cardiologs Technologies™, Paris, France) is a cloud-
21 based platform for ECG interpretation powered by a deep neural network algorithm. This algorithm
22 has already been validated, especially for 12 lead-ECG interpretation in emergency departments,[7]
23 diagnosis of atrial fibrillation,[8] and for Holter analysis.[9] An analog watch with an in-built single-
24 lead ECG (Withings Move ECG™, Withings, France), linked to the Cardiologs™ AI platform, can send
25 self-recorded ECGs direct for AI analysis.

1 We performed a study to compare QTc assessed using this algorithm on smartwatch single-lead ECGs
2 (AI-QTc) with QTc measured using conventional 12-lead ECGs in patients with early stage coronavirus
3 disease 2019 (COVID-19) treated with the HCQ–AZM regimen.

4

5 METHODS

6 We identified all consecutive adults (≥ 18 years) who attended the ambulatory care center of the
7 infectious diseases department of our tertiary referral academic hospital from April 16 to April 24,
8 2020, for polymerase chain reaction (PCR)-positive SARS-CoV-2 infection. Medical history and current
9 medical status were thoroughly assessed for each patient and the decision to treat with HCQ–AZM
10 was taken by the infectious disease specialist. The study is registered at ClinicalTrials.gov, with the
11 unique identifier NCT04371744. The study was reviewed by the medical research committee of our
12 academic hospital (reference number 2020-52) and approved by the ethical committee (reference
13 number: 2020-030). Signed written informed consent was obtained from all participants.

14

15 Cardiac-Rhythm Safety evaluation:

16 Once the decision to treat was taken, according to local guidelines, Tisdale Score and recent
17 recommendations [3, 10] a rhythm safety evaluation was systematically performed to assess QTc
18 prolongation risk. Moreover, treatment with HCQ–AZM was not started if the corrected QT interval
19 (QTc; Bazett's formula) was >500 ms, or if the ECG showed patterns suggesting a channelopathy, or if
20 other significant abnormalities (i.e., pathological Q waves, left ventricular hypertrophy, left bundle
21 branch block) were present. The risk–benefit ratio of HCQ–AZM was estimated by the infectious
22 disease specialist and agreed upon with the cardiologist, for a range between 460 and 500 ms of QTc.
23 In addition, any drug with the potential to prolong the QT interval was discontinued or replaced with
24 another drug for the treatment course. Standard blood chemistry was checked, especially serum

1 creatinine and kalemia in the context of SARS-CoV-2, and the treatment was not started when there
2 was hypokalemia with a serum potassium <3 mEq/L, and was discontinued at day 1 if the serum
3 potassium between 3 and 3.5 mEq/l was not normalized.

4

5 ECG recording:

6 All patients who were prescribed HCQ–AZM treatment and had no criteria for overnight stay were
7 considered for inclusion in the study if they had a smartphone and were able and willing to perform
8 repeated SW-ECGs. They received a smartwatch (Withings Move ECG™) and were instructed on how
9 to use it. A 12-lead ECG was then recorded at rest (baseline), with a paper speed of 50 mm/s and an
10 amplitude calibration of 10 mm/mV (MAC® 3500 or MAC® 1600 recorder; GE Healthcare Europe,
11 Freiburg, Germany). As soon as technically possible, an ECG recording was taken with the
12 smartwatch. Patients were then allowed to go home. The drug regimen was as follows:
13 hydroxychloroquine (Plaquenil®; Sanofi Aventis, Paris, France), 200 mg three times per day for 10
14 days, plus azithromycin (Zithromax®; Pfizer Holding, Paris, France), 500 mg once a day on the first
15 day, then 250 mg once a day for 4 days.

16 The patients were instructed to transmit a SW-ECG every morning at rest and at any time in case of
17 unusual symptoms, including palpitations or dizziness, until the end of the treatment. As per local
18 guidelines, patients were requested to attend a follow-up visit at the ambulatory care center of the
19 infectious disease department for clinical assessment and a 12-lead ECG on the sixth day (day-6,
20 recommended) and on the last day of therapy (day-10, mandatory). They transmitted a SW-ECG as
21 soon as technically possible after the 12-lead ECG recording at day-6 and day-10 (Figure 1).

22

23 Electrocardiogram Interpretation

24 Manual Interpretation

1 On the standard 12-lead ECG recordings obtained at baseline, day-6 and day-10, the QT interval was
2 measured, as recommended[11] in the tangent method, in lead II or V5, and corrected using Bazett's
3 formula. In addition, QTc was assessed on lead I using the same method. Additional measurement
4 included heart rate, and any cases of arrhythmia were recorded. PR interval and QRS duration were
5 measured only at baseline and day-10. The interpretation was blindly performed by two
6 cardiologists, (B.M.) and (M.W.). When there was a <30 ms discrepancy between the 2 measures, the
7 mean of the 2 values obtained by the 2 operators was used to compare against the AI-based
8 automatic measurement of QTc. When there was a >30 ms discrepancy between the 2 measures, an
9 additional cardiologist (J-C.D.) performed the measure and this value was used for comparison
10 against the AI-QTc.

11 The QT interval was manually measured on daily SW-ECGs, using the same method as described
12 above for 12-lead ECGs and compared with the AI-QTc measurements. In addition, manual
13 measurement of the QTc was performed independently by 3 electrophysiologists (B.M., M.W. and
14 L.F.) on the transmitted SW-ECG from day-10. Manual measurements were performed blinded to the
15 AI interpretation, and the mean of the 3 measured values was used for comparison with AI-QTc. In
16 case of SW-ECG transmission due to symptoms, the ECG was interpreted by the same cardiac
17 electrophysiologists. Patients could be contacted in the event of a significant arrhythmia or QTc
18 prolongation >500 ms.

19

20 Artificial intelligence Interpretation

21 AI-QTc were systematically measured from all received SW-ECG. When the 30-s SW-ECG was
22 performed by a patient, it was automatically transmitted to the Cardiologs platform for assessment
23 of the AI-QTc. The AI-QTc was computed as follows: a deep convolutional neural network identified
24 the onset of QRS complexes and the offset of following T waves of all beats in the SW-ECG. The QTc
25 of each beat was computed with the Bazett formula, using the QT and the preceding RR intervals

1 detected by the neural network. Finally, in order to remove extreme and aberrant values, the AI-QTc
2 of the SW-ECG was computed as the median QTc across all beats.

3 The convolutional neural network consists of a U-net architecture[12] with 11 convolutional layers
4 and 6 residual blocks. The network takes as input the ECG signal and outputs the onsets and offsets
5 of all detected P, QRS and T waves. The network was trained on 6315 resting ECGs and Holter
6 recordings, with the onsets and offsets of P, QRS and T waves annotated by experts in
7 electrophysiology following standard procedures. No SW-ECG was used during training of the neural
8 network. The SW-ECGs were single lead ECGs lasting 30 s and sampled at 300 Hz, a sampling rate
9 which is similar to the recordings used for training (100 to 500 Hz). The network was implemented in
10 Keras, with a backend in Tensorflow (Google, Mountainview, California), and trained using stochastic
11 gradient descent. Early stopping and dropout regularization were used to avoid overfitting.[13] In
12 order to ensure that the network performs accurately for multiple and single lead ECGs, leads were
13 sometimes randomly subsampled during training. The performance of the AI-QT measurement was
14 evaluated on the Common Standards for Quantitative Electrocardiography database.[14] The bias of
15 the QT measurement was -13.7 ms, with a standard deviation of 7.3 ms.

16 Outcome Measures

17 The primary outcome was the agreement between the standard 12-lead QTc interval measured
18 manually in lead II or V5 at baseline and day-10, and the AI-QTc measured on the corresponding SW-
19 ECG.

20 Secondary outcomes included the agreement between the standard 12-lead QTc measured manually
21 in lead II or V5 at the day-6 visit and the AI-QTc on the corresponding SW-ECG; agreement between
22 the 12-lead QTc measured manually in lead I at baseline, day-6 and day-10 and the AI-QTc on the
23 corresponding SW-ECG; agreement between the QTc measured by the cardiologist on the daily SW-
24 ECG and the AI-QTc on the same SW-ECG, at day-10; and a description of QTc behavior during HCQ-

1 AZM therapy and of arrhythmia occurrence as assessed on daily SW-ECGs or on-demand SW-ECGs
2 (i.e. in case of symptoms).

3

4 Statistical Analysis

5 Quantitative variables are presented as means \pm standard deviations (SD) and categorical variables as
6 numbers (percentages). Agreement between QTc measurements (between manual QTc
7 measurement on the 12-lead ECGs and AI-QTc, between QTc measured manually on the same SW-
8 ECG and AI-QTc) was assessed using the Bland-Altman method. The mean of the difference (bias) in
9 QTc interval between the 2 methods was calculated, as well as the lower and upper limits of
10 agreement. Agreement between measures was also numerically assessed by estimating the
11 agreement intraclass correlation coefficient (ICC), with its 95% confidence interval (CI). Daily
12 smartwatch QTc were compared with baseline smartwatch QTc by means of a paired t-test. The
13 Benjamini–Hochberg procedure was used for controlling the false positive rate in multiple
14 comparisons.

15 All analyses were performed using R software, version 3.6.3. All tests were 2-sided, and $P < 0.05$ was
16 considered statistically significant.

17

18 RESULTS

19 Between April 16 and April 24, 2020, 108 consecutive adults with a PCR-positive SARS-CoV-2
20 infection with no criteria for overnight stay were considered for HCQ–AZM combination therapy
21 initiated at our infectious disease ambulatory care department. The patient flow chart is illustrated in
22 Supplemental figure 1. Of the 85 patients who entered the study, 76 received the drug regimen and
23 were followed with daily SW-ECGs. The epidemiological, clinical, and baseline ECG characteristics of
24 the patient populations are presented in Table 1. In 3 patients (3.9%), serum potassium was between

1 3 and 3.5 mmol/L at inclusion; they received potassium supplementation, achieving normo-kalemia
2 after 1 day, and could continue the treatment. Ten patients (13.1%) were taking concomitant QT-
3 prolonging drugs (antihistamine drugs) and 2(2.6%) were taking beta-blockers. These treatments
4 were all discontinued on the decision of the infectious disease specialist as they were not considered
5 essential. No patient had a significant ECG abnormality or underlying severe cardiac disease. Among
6 patients who received the drug regimen and were followed with daily SW-ECGs, median Tisdale score
7 was 7 (6-7). Respectively 26(34.2%), 50(65.8%) and 0(0%) presented a low, moderate and high risk of
8 prolonging QTc.

9 Mean follow-up was 10.8 ± 1.2 days. One patient had to be admitted to the conventional ward
10 because of a deterioration in his respiratory function at day 5 of treatment and stayed in hospital for
11 5 days. No more SW-ECGs were recorded after he was admitted to the hospital, but clinical follow-up
12 and a 12-lead ECG at day 10 were still available. By their own decision, 17(22.4%) patients did not
13 attend the optional day-6 visit and 2(2.6%) did not attend day-10 visit. They were contacted at day-
14 10, and it was confirmed that they did not experience palpitations or syncope. One patient declared
15 a minor cutaneous allergic reaction with pruritus related to the watch strap, which did not prevent
16 the patient from sending daily recordings. With this exception, no patient declared any difficulty in
17 the wearing the smartwatch.

18 Owing to technical issues in communication between their smartwatch and smartphone, 5/71(6.6%),
19 5/53(8.6%) and 7/66(9.6%) patients were unable to record a SW-ECG after the 12 lead-ECG during
20 the visit at baseline, day-6, and day-10, respectively. A mean of 9.5 ± 2.1 SW-ECGs were recorded per
21 patient. Fifty (65.8%) patients performed at least 10 SW-ECGs during the 11 days of follow-up, while
22 6(7.9%) performed fewer than 6 SW-ECGs. No patient reported palpitations, dizziness, or syncope.
23 The number of patients in whom 12-lead and SW-ECGs could be compared at each visit is detailed in
24 Table 2.

25

1 Agreement Between Manual and AI-QTc Intervals

2 The delay between completion of the standard 12-lead ECG and the SW-ECG was 55.7 ± 141.3 min at
3 baseline, 38.2 ± 129.1 min at day-6, and -2.6 ± 64.7 min at day-10. Table 2 shows the agreement
4 between the manually measured QTc on the 12-lead ECG, the manually measured QTc on lead I of
5 the same tracing, and AI-QTc from the corresponding SW-ECG. When the delay between completion
6 of the 12-lead ECG and the SW-ECG was the shortest, at day-10, the Bland-Altman diagram (Table 2,
7 Figure 2B) showed the best agreement. Similar results were obtained at day-6 (Table 2, Supplemental
8 Figure 2). The difference between the two measures was <50 ms in 65(98.2%) patients at day-10 and
9 in 51(96.2%) patients at day-6. At baseline, 69(97.2%) patients presented with a lower than 50 ms
10 difference between the two measures. However, the agreement assessed by the Bland-Altman was
11 lower (Table 2, Figure 2A). Consistently across the three visits, the agreement between the QTc
12 measured in lead I and the AI-QTc showed a tendency to overestimate QTc, with a similar limit of
13 agreement to 12 lead ECG (Table 2, Supplemental figure 3).

14 Agreement was excellent between the AI-QTc at day 10 and the manual measure of QTc on the same
15 recording (Supplemental figure 4), showing a bias (limits of agreement) of 0 ($-18, +17$) ms and an ICC
16 agreement (95% CI) of 0.91 (0.85, 0.94).

17

18 QTc Behavior During Treatment

19 Figure 3 illustrates daily AI-QTc behavior, during HCQ-AZM therapy. Compared to the baseline value,
20 there was no significant daily prolongation of QTc during treatment (Figure 3A). Similar results were
21 obtained for QTc interval behavior as manually measured on the 12-lead ECGs (Figure 3B). At the
22 individual level, as compared to baseline: 18(23.4%), 5(6.5%) and 7(9.1%) patients had at least one
23 daily SW-QTc prolonged by, respectively, 20–40 ms, 40–60 ms, and >60 ms. In the meantime, only
24 29(39.1%), 10(13.6%), and 1(1.4%) were identified by the standard 12-lead ECGs during the follow-
25 up.

1 One patient had a AI-QTc >500 ms (i.e. 502 ms) on the second day of treatment and was therefore
2 admitted to the day-hospital. The 12-lead ECG showed a prominent U wave in lead I, along with a low
3 T-wave amplitude. In this patient, baseline 12-lead QTc interval was 457 ms and no AI-QTc was
4 available at baseline because of pairing issues between the smartphone and the smartwatch. The 12-
5 lead QTc measured in hospital on day 2 was 471 ms, thus the drug regimen was continued at home.
6 No QTc value >500 ms was observed on either the subsequent daily AI-QTc or 12-lead ECGs during
7 follow-up.

8 In the general population, a slight but significant PR prolongation was observed at day-10 (154 ± 25 ms
9 at baseline to 161 ± 23 ms at day-10; $P<0.001$). There was no significant QRS prolongation from
10 baseline (83 ± 19 ms) to day-10 (86 ± 17 ms) ($P=0.3$).

11 Four patients (5.2%) presented with asymptomatic premature ventricular contractions (PVC) on their
12 daily SW-ECGs. All of them had also had such PVC's on their 12 lead-ECG at baseline. No other
13 arrhythmia was identified during follow-up.

14

15 DISCUSSION

16 We observed a fair agreement between the QTc interval duration measured manually on a standard
17 12-lead ECG and assessed by AI on single-lead smartwatch recordings. This agreement was observed
18 on different sets of tracings obtained at various points throughout the study, provided they were
19 recorded at similar times. In this young population of patients with early stage COVID-19 and mild-to-
20 moderate symptoms, no significant QTc prolongation was observed on daily AI-QTc and no life-
21 threatening arrhythmias were reported. Whereas one study has already demonstrated the power of
22 a deep learning algorithm for diagnosis of arrhythmia,[4] the current is the first to evaluate a deep
23 neural network with SW-ECGs for QT monitoring.

1 A few studies[15, 16] and recent recommendations[17] have highlighted the major interest of using
2 connected devices in the context of the potential use of QT-prolonging drugs in COVID-19 therapy.
3 Previous studies described the utility of various connected ECG recording devices, such as
4 smartphones,[15, 18] wearable remote monitoring systems,[19] smartwatches,[6] and mobile
5 cardiac telemetry[16] for QTc monitoring. Some have also described the use of automatic
6 measurement of the QTc using different automatic algorithms, but not neural network-based AI,
7 embedded on recording devices or proprietary. Our study is the first to confirm the feasibility and
8 accuracy of a neural network-based AI-QTc determination, using ECG independently gathered from
9 direct-to-consumer SW-ECG, in real-life conditions of COVID-19 therapy.

10 Agreement between 12-lead ECG and a SW-ECG QTc measurements have been shown to be
11 dependent on factors such as ECG tracing quality and T-wave amplitude.[6] Different strategies of
12 improving agreement accuracy have been described. Strik et al. used “T-wave mapping” screening to
13 identify the best smartwatch position and withdrew from their study patients in whom the different
14 smartwatch positions did not allow for adequate measurement.[6] Other investigators excluded
15 patients with poor quality of reference ECG tracing. In our real life study, no patient was excluded
16 based on the shape or quality of the SW-ECG, and only standard recording (i.e. with the watch worn
17 on the wrist) was performed. Moreover, no SW-ECG was used during training of our neural network.
18 Due to the COVID 19 pandemic emergency situation, there was not enough time to apply such a
19 strategy of specific neural network training. Despite this imperfect emergency protocol, we found a
20 fair agreement with manual-QTc, comparable to that reported in the literature.[6, 15-17, 20]. We
21 expect the use of a specific AI trained with SW-ECGs would demonstrate more accurate agreement.

22 There are numerous sources of potential discrepancy in QTc interval assessment, ranging from
23 interobserver variability and precision of the measurement technology to intrinsic variability of the
24 QTc itself. The discrepancy between manual QTc measurements, even when performed by experts, is
25 wide, ranging from 34 to 80 ms.[20] In addition, QT interval is a highly dynamic parameter, showing

1 well-known circadian variations. Apart from heart rate itself, it is highly sensitive to autonomic
2 nervous system influences[21] and to many pathologic conditions such as ischemia.[22] Even if we
3 did our best to perform smartwatch and 12-lead ECG recordings as close in time as possible, a
4 significant delay was observed in some cases for various reasons that may reflect real life. In spite of
5 a potential multifactorial QTc variability in measurements, we found acceptable agreement.

6 As the SW-ECG records a lead equivalent to lead I of the ECG, we were expecting stronger agreement
7 between AI and manual QTc when the measure was performed in lead I. AI-QTc was consistently
8 overestimated compared with lead 1 QTc, but a similar limit of agreement with 12-lead QTc was
9 observed. There is no clear explanation, but we assume that it might be due to the fact that lead I is
10 not optimal for QT measurement for various reasons, including the shape or amplitude of the T wave
11 in lead I, and the QT dispersion on a 12-lead ECG.[23, 24] We believe that AI may compensate for
12 some of these issues by computing a median over all beats, removing the extreme and aberrant
13 values, whereas manual measurement only relies on a few beats.

14 While HCQ effectiveness in COVID-19 is criticized,[25] its use in connective tissue disease is wide[26]
15 and antiviral strategies in COVID-19 still unresolved. Moreover this study was not designed to test
16 the effectiveness of HCQ–AZM in COVID-19 but rather to examine cardiac safety profile of such
17 medication. The use of HCQ–AZM in patients with early stage COVID-19 with mild-to-moderate
18 symptoms in an ambulatory care center, was not related with significant prolongation of the QTc
19 interval during the drug regimen or significant arrhythmia occurrence. However, HCQ may lead to QT
20 prolongation. HCQ is a derivative of chloroquine and has similarities to quinine, which is a class Ia
21 antiarrhythmic drug that acts as a sodium channel blocker, responsible for prolonging the duration of
22 the action potential, and may therefore prolong the QT interval. However, this effect is expected to
23 be modest.[27] AZM has low affinity for the hERG channel,[28] and is therefore considered to have a
24 low risk of QT prolongation. However, combining both drugs, particularly when taking into account
25 the increased risk of electrolyte disorders in patients with severe COVID-19, may result in a

1 proarrhythmic effect. Recent publications[29, 30] evaluating HCQ–AZM treatment in hospitalized
2 patients with COVID-19, with a mean age greater than 60 years, and including severe and critically ill
3 patients with COVID-19, have shown important QTc lengthening in some patients. However, other
4 evaluating lower risk patients,[31] similarly to our study, showed only modest QTc prolongation. This
5 highlighted the necessity of an initial QTc prolongation risk evaluation and a close QTc monitoring,
6 for patients under prolonging QTc drugs. Thus a home-monitoring ECG is of greatest interest, in the
7 context of the required social distancing, because of the COVID-19 pandemic.

8

9 Limitations

10 One of the limitations of our study is the very low number of critical QTc prolongations. This is likely
11 due to our cardiac-rhythm safety criteria for HCQ–AZM therapy. Although the accuracy for
12 monitoring pathologic QTc prolongation remains uncertain, the agreement we found makes it a
13 promising strategy.

14 Our study also highlights some limitations of SW-ECG follow-up, including willingness and capacity to
15 participate, technical skills, and adequate internet coverage. Twelve patients were not included
16 because of an anticipated poor adherence to the study protocol (either related to patient choice or
17 understanding), and 7 additional patients were withdrawn for technical issues after inclusion. A small
18 number of patients occasionally did not transmit daily SW-ECG data. Finally, as previously
19 mentioned, owing to poor internet coverage in the daycare facility, simultaneous 12-lead ECGs and
20 SW-ECGs were unpredictively not feasible. Despite these issues, participation in the study was good,
21 but different study populations, especially older people, may show more technical difficulties.

22 Since the determination of QTc duration by an ECG recorder is commonly used, we could have
23 compared the values obtained by AI to the values automatically determined by the ECG recorder.

24 However, the latter are specific to each ECG recorder and cannot be taken as reference since their
25 accuracy is debated.[32, 33] On the other hand, manual measurement is the gold standard for QT

1 measurement[11], and for this reason we used it for comparison. We see a major benefit of neural
2 network-based QTc determination since it is device-independent and, therefore, generalizable to all
3 ECG recordings having the same characteristics than our SW-ECGs.

4 CONCLUSIONS

5 This first “real-world” study evaluating a neural network-based AI-assessed QTc measurement,
6 gathered from direct-to-consumer smartwatches, shows promising results. Despite variability in the
7 QTc interval, fair agreement was observed between AI and 12-lead ECGs. The use of AI-QTc follow-up
8 could potentially avoid life-threatening arrhythmias by stopping treatments that can cause QT
9 prolongation before occurrence of symptoms. This finding also has the potential to lead to future
10 clinical applications in the evaluation of any drug-induced arrhythmogenicity related with QT
11 prolongation, needing close QT interval monitoring.

12

1 REFERENCES

- 2
- 3 [1] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults
4 Hospitalized with Severe Covid-19. *N Engl J Med.* 2020;382:1787-99.
- 5 [2] Naksuk N, Lazar S, Peeraphatdit TB. Cardiac safety of off-label COVID-19 drug therapy: a review
6 and proposed monitoring protocol. *Eur Heart J Acute Cardiovasc Care.* 2020;9:215-21.
- 7 [3] Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for Drug Interactions on QTc
8 Interval in Exploratory COVID-19 Treatment. *J Am Coll Cardiol.* 2020;75:2623-4.
- 9 [4] Hannun AY, Rajpurkar P, Haghpanahi M, Tison GH, Bourn C, Turakhia MP, et al. Cardiologist-level
10 arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural
11 network. *Nat Med.* 2019;25:65-9.
- 12 [5] Chung EH, Guise KD. QTC intervals can be assessed with the AliveCor heart monitor in patients on
13 dofetilide for atrial fibrillation. *J Electrocardiol.* 2015;48:8-9.
- 14 [6] Strik M, Caillol T, Ramirez FD, Abu-Alrub S, Marchand H, Welte N, et al. Validating QT-Interval
15 Measurement Using the Apple Watch ECG to Enable Remote Monitoring During the COVID-19
16 Pandemic. *Circulation.* 2020;142:416-8.
- 17 [7] Smith SW, Walsh B, Grauer K, Wang K, Rapin J, Li J, et al. A deep neural network learning
18 algorithm outperforms a conventional algorithm for emergency department electrocardiogram
19 interpretation. *J Electrocardiol.* 2019;52:88-95.
- 20 [8] Smith SW, Rapin J, Li J, Fleureau Y, Fennell W, Walsh BM, et al. A deep neural network for 12-lead
21 electrocardiogram interpretation outperforms a conventional algorithm, and its physician overread,
22 in the diagnosis of atrial fibrillation. *Int J Cardiol Heart Vasc.* 2019;25:100423.
- 23 [9] Fiorina L, Marijon E, Maupain C, Coquard C, Larnier L, Rischard J, et al. Abstract 9825: Artificial
24 Intelligence Based Platform Enables Faster Ambulatory Electrocardiogram Analysis With Equivalent
25 Clinical Accuracy Compared to Traditional Solution. *Circulation.* 2019;140:A9825-A.
- 26 [10] Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and
27 validation of a risk score to predict QT interval prolongation in hospitalized patients. *Circ Cardiovasc*
28 *Qual Outcomes.* 2013;6:479-87.
- 29 [11] Postema PG, De Jong JS, Van der Bilt IA, Wilde AA. Accurate electrocardiographic assessment of
30 the QT interval: teach the tangent. *Heart Rhythm.* 2008;5:1015-8.
- 31 [12] Srivastava N, Hinton G, Krizhevsky A, Sutskever I, Salakhutdinov R. Dropout: a simple way to
32 prevent neural networks from overfitting. *J Mach Learn Res.* 2014;15:1929-58.
- 33 [13] Srivastava N HG, Krizhevsky A, Sutskever I, Salakhutdinov R. Dropout: A Simple Way to Prevent
34 Neural Networks from Overfitting. *J Mach Learn Res.* 2014;15:1929-58.
- 35 [14] Smisek R, Marsanova L, Nemcova A, Vitek M, Kozumplik J, Novakova M. CSE database: extended
36 annotations and new recommendations for ECG software testing. *Med Biol Eng Comput.*
37 2017;55:1473-82.
- 38 [15] Cheung CC, Davies B, Gibbs K, Laksman ZW, Krahn AD. Multilead QT Screening Is Necessary for
39 QT Measurement: Implications for Management of Patients in the COVID-19 Era. *JACC Clin*
40 *Electrophysiol.* 2020;6:878-80.
- 41 [16] Saleh M, Gabriels J, Chang D, Soo Kim B, Mansoor A, Mahmood E, et al. Effect of Chloroquine,
42 Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2
43 Infection. *Circ Arrhythm Electrophysiol.* 2020;13:e008662.
- 44 [17] Varma N, Marrouche NF, Aguinaga L, Albert CM, Arbelo E, Choi JJ, et al.
45 HRS/EHRA/APHRS/LAHRs/ACC/AHA worldwide practice update for telehealth and arrhythmia
46 monitoring during and after a pandemic. *Europace.* 2020.
- 47 [18] Garabelli P, Stavrakis S, Albert M, Koomson E, Parwani P, Chohan J, et al. Comparison of QT
48 Interval Readings in Normal Sinus Rhythm Between a Smartphone Heart Monitor and a 12-Lead ECG
49 for Healthy Volunteers and Inpatients Receiving Sotalol or Dofetilide. *J Cardiovasc Electrophysiol.*
50 2016;27:827-32.

- 1 [19] Castelletti S, Dagradi F, Goulene K, Danza AI, Baldi E, Stramba-Badiale M, et al. A wearable
2 remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for
3 drug-induced long QT syndrome. *Int J Cardiol.* 2018;266:89-94.
- 4 [20] Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM, et al. Inaccurate
5 electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT
6 when they see one. *Heart Rhythm.* 2005;2:569-74.
- 7 [21] Murakawa Y, Inoue H, Nozaki A, Sugimoto T. Role of sympathovagal interaction in diurnal
8 variation of QT interval. *Am J Cardiol.* 1992;69:339-43.
- 9 [22] Puljevic D, Smalcelj A, Durakovic Z, Goldner V. QT dispersion, daily variations, QT interval
10 adaptation and late potentials as risk markers for ventricular tachycardia. *Eur Heart J.* 1997;18:1343-
11 9.
- 12 [23] Baumert M, Porta A, Vos MA, Malik M, Couderc JP, Laguna P, et al. QT interval variability in body
13 surface ECG: measurement, physiological basis, and clinical value: position statement and consensus
14 guidance endorsed by the European Heart Rhythm Association jointly with the ESC Working Group
15 on Cardiac Cellular Electrophysiology. *Europace.* 2016;18:925-44.
- 16 [24] Cowan JC, Yusoff K, Moore M, Amos PA, Gold AE, Bourke JP, et al. Importance of lead selection
17 in QT interval measurement. *Am J Cardiol.* 1988;61:83-7.
- 18 [25] Maisonnasse P, Guedj J, Contreras V, Behillil S, Solas C, Marlin R, et al. Hydroxychloroquine use
19 against SARS-CoV-2 infection in non-human primates. *Nature.* 2020;585:584-7.
- 20 [26] Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine:
21 implications for rheumatology. *Nat Rev Rheumatol.* 2020;16:155-66.
- 22 [27] Lakkireddy DR, Chung MK, Gopinathannair R, Patton KK, Gluckman TJ, Turagam M, et al.
23 Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm
24 Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and
25 the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American
26 Heart Association. *Circulation.* 2020;141:e823-e31.
- 27 [28] Hancox JC, Hasnain M, Vieweg WV, Crouse EL, Baranchuk A. Azithromycin, cardiovascular risks,
28 QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the
29 study of case reports. *Ther Adv Infect Dis.* 2013;1:155-65.
- 30 [29] Bessiere F, Rocca H, Deliniere A, Charriere R, Chevalier P, Argaud L, et al. Assessment of QT
31 Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated
32 With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.
33 *JAMA Cardiol.* 2020;5:1067-9.
- 34 [30] Chorin E, Wadhvani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, et al. QT interval
35 prolongation and torsade de pointes in patients with COVID-19 treated with
36 hydroxychloroquine/azithromycin. *Heart Rhythm.* 2020;17:1425-33.
- 37 [31] Gasperetti A, Biffi M, Duru F, Schiavone M, Ziacchi M, Mitacchione G, et al. Arrhythmic safety of
38 hydroxychloroquine in COVID-19 patients from different clinical settings. *Europace.* 2020.
- 39 [32] Diamant UB, Winbo A, Stattin EL, Rydberg A, Kesek M, Jensen SM. Two automatic QT algorithms
40 compared with manual measurement in identification of long QT syndrome. *J Electrocardiol.*
41 2010;43:25-30.
- 42 [33] McLaughlin NB, Campbell RW, Murray A. Comparison of automatic QT measurement techniques
43 in the normal 12 lead electrocardiogram. *Br Heart J.* 1995;74:84-9.

1 **Figure Legends**

2

3 **Figure 1. (Central illustration) Schematic of the Study Protocol and Operation of the**
4 **Cardiologs® System.**

5 AZM denotes azithromycin; ECG, electrocardiogram; HCQ, hydroxychloroquine; PCR, polymerase
6 chain reaction; and SW-ECG, smartwatch electrocardiogram.

7

8 **Figure 2. Comparison of QT-Interval Measurements, using QTc Measured Manually on the 12-**
9 **Lead ECG and AI-Determined QTc Based on Smartwatch Recordings, at (A) Baseline and (B)**
10 **Day-10. The Bland–Altman Method was Used for Analysis of Measurement Agreement.**

11 Solid blue and dashed red lines represent the bias limit of agreement in the QTc interval between the
12 2 methods. 12-lead QTc denotes QTc interval measured on a 12-lead ECG; AI artificial intelligence;
13 and ECG, electrocardiogram.

14

15 **Figure 3. QTc Behavior With Hydroxychloroquine–Azithromycin Combination Treatment in a**
16 **Daycare Population with COVID-19.**

17 (A) Daily SW-QTc measured by AI. (B) QTc measured manually on a 12-lead ECG. In both cases all
18 changes were non-significant versus baseline.

19 12-lead QTc denotes QTc interval measured on a 12-lead ECG; AI, artificial intelligence; COVID-19,
20 coronavirus disease 2019; and SW-QTc, QTc interval measured on a Smartwatch ECG.

21

22

1 **Table 1. Patient Characteristics**

Characteristic	Overall Population (n=85)	Patients on HCQ–AZM combination and daily SW-ECG (n=76)
Male sex	30(35.3)	27(35.5)
Mean age, y	38.3±12.2	38.2±12.4
≥65 y	0(0)	0(0)
Body mass index, kg/m ²	26.4±5.4	26.6±5.7
Cardiovascular risk factor		
Hypertension	4(4.7)	4(5.3)
Diabetes mellitus	2(2.4)	2(2.6)
Active smoker	19(22.3)	17(22.4)
Clinical setting		
Oxygen saturation <94%	1(1.2)	1(1.3)
Systolic blood pressure, mmHg	128±16	129±16
Fever (>38 °C)	7(8.2)	6(7.9)
Cardiovascular treatment		
ACE inhibitor/ARB	2(2.4)	2(2.6)
Beta-blocker	2(2.4)	2(2.6)

2 For continuous variables, values are mean±standard deviation; for categorical variables, n(%) is

3 shown.

4 ACE denotes angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; HCQ–AZM,

5 hydroxychloroquine plus azithromycin combination; and SW-ECG, smartwatch electrocardiogram.

1 **Table 2. Comparison Between 12 Lead-QTc Measured Manually and Automatically Assessed**
 2 **QTc From the Corresponding SW-ECG.**


ECG type	Time	QTc, mean \pm SD, ms		Bias between measures (95% LoA) (ms)	ICC agreement	
		Manually measured on ECG	AI-determined on SW recording		(95% CI)	P Value
12 leads	Baseline (n=71)	402 \pm 27	407 \pm 25	-5(-54,+43)	0.54(0.35,0.68)	<0.001
	Day-6 (n=53)	405 \pm 23	406 \pm 25	-1(-45,+43)	0.57(0.35,0.72)	<0.001
	Day-10 (n=66)	407 \pm 26	407 \pm 22	-1(-46,+45)	0.54(0.34,0.69)	<0.001
Lead I	Baseline (n=71)	385 \pm 27	407 \pm 25	-23(-74,+28)	0.38(0.01,0.62)	0.02
	Day-6 (n=53)	393 \pm 26	406 \pm 25	-14(-58,+31)	0.53(0.22,0.72)	<0.001
	Day-10 (n=66)	395 \pm 27	407 \pm 22	-13(-57,+32)	0.50(0.22,0.69)	<0.001

3 AI denotes artificial intelligence; CI, confidence interval; ECG, electrocardiogram; ICC, interclass
 4 correlation coefficient; LoA, limits of agreement; and SW, smartwatch.


5

1 **Figure 1 (central illustration)**

2





B **QT measurements sources**



3

1 **Figure 2**




2

3

1 **Figure 3**

2



3

4

5